A Multidisciplinary Approach to Data Standards for Clinical Development--Progress Update

The pharmaceutical industry spends more than $156 million each year to support data transfer, and all involved parties could benefit from common interchange standards.

External Link - article-13739.pdf

Articles in this issue

over 24 years ago

Article

When Process Improvement is Skin-Deep

over 24 years ago

Article

Communicating in the Information Age: It?s Still All About Human Behavior

over 24 years ago

Article

Terrorists Steal Limelight from Human Subjects

over 24 years ago

Article

A Rose by Any Other Name

over 24 years ago

Article

European Change Is Still in the Air

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

A Multidisciplinary Approach to Data Standards for Clinical Development--Progress Update

Articles in this issue

Related Content

FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy

Why Rebuilding Patient Pipelines from Scratch for Every Study Has to Stop

Bringing the Voice of Clinical Practice and Patients into Drug Development

ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion

Tailoring Your FSP Approach: Why One Model Doesn’t Fit Every Trial

Trending on Applied Clinical Trials Online

FDA Pauses Real-Time Release of Drug Rejection Letters While Working to Formalize Policy

Bringing the Voice of Clinical Practice and Patients into Drug Development

ACT Brief: Single Pivotal Trial Stakes, Configurable FSP Strategy, and G-CSF Biosimilar Portfolio Expansion

Tailoring Your FSP Approach: Why One Model Doesn’t Fit Every Trial

ACT Brief: Simplifying Trials Through Selective Safety Data, AI-Driven Site Partnerships, and Biopharma Strategic Pivots